Analysis of healthcare resource use of the robotic surgery system for rectal cancer in Japan

Hiroshi Yoshihara [1], Ataru Igarashi [1], Daniel D'Attilio[2], Minkyung Shin [2], Kyoko Mizutani [2]
1 Dept. of Health Economics and Outcomes Research, The University of Tokyo, Tokyo, Japan
2 Intuitive Surgical Inc., Sunnyvale, CA, US

ISPOR Europe 2022

Objectives

The robot-assisted surgery system has the potential to overcome the limitations of existing low-invasive surgical systems with regard to operatability and precision of maneuvers.

Da Vinci system (dV), the robot-assisted surgery system produced by Intuitive Surgical Inc., was reimbursed for lobectomy for rectal cancer in Japan since Apr 2018, without any premiums. Additional evidence of relative benefits for patients is necessary for premiums.

Our objective is to assess the healthcare resource use of the dV against open surgery and laparoscopic (LAP) low anterior resection (LAR) surgery for rectal cancer patients in Japan.

Design and method

For this study, hospital-based claims data with DPC (DRG-like flat payment system) were obtained from Medical Data Vision Co., Ltd. Patients with lung cancer who received either open surgery, LAP surgery, or dV were included for the analysis.

Propensity score matching (PSM) was performed to adjust for patient background biases. PSM incorporated six factors age, gender, BMI, smoking history, stage of disease based on TNM classification, and Charlson Comorbidity Index (CCI).

The following components of healthcare resource use were measured: the length of hospitalization (entire length and length after surgery), medical costs (index hospitalization, total cost after 30/90/365 days of discharge). The following health-related outcomes were also compared: surgical site infection, transfusion, post-operative pain, post-operative complications, readmission.

Results: open surgery vs dV surgery

	Before PSM			After PSM		
	Open (n=2485)	dV (n=1572)	P value	Open (n=1304)	dV (n=1304)	P value
Age, mean (SD)	68.3 (11.9)	65.7 (11.6)	**<0.001**	66.8 (12.1)	67.1 (11.4)	0.85
Female, n (%)	916 (36.9)	553 (35.2)	0.29	485 (37.2)	467 (35.8)	0.49
BMI, mean (SD)	22.5 (3.81)	22.9 (3.69)	**<0.001**	22.8 (4.06)	22.7 (3.60)	0.74
Smoking history, n (%)	1247 (50.1)	887 (56.4)	**<0.001**	696 (53.4)	706 (54.1)	0.72
Stage, n (%)						
1	428 (17.2)	638 (40.6)	**<0.001**	369 (28.3)	371 (28.5)	0.97
2	699 (28.1)	360 (22.9)	**<0.001**	329 (25.2)	360 (27.6)	0.18
3	879 (35.4)	472 (30.0)	**<0.001**	498 (38.2)	471 (36.1)	0.29
4	457 (18.4)	91 (5.79)	**<0.001**	97 (7.43)	91 (6.98)	0.71
CCI, mean (SD)	7.77 (3.90)	6.93 (3.70)	**<0.001**	7.22 (3.88)	7.28 (3.73)	0.92

Table 1

	Open (n=1304)	dV (n=1304)	P value
Total length of hospitalization, mean (SD)	26.0 (22.0)	18.4 (9.79)	**<0.001**
Length after surgery, mean (SD)	22.3 (21.1)	15.7 (9.54)	**<0.001**
Total cost of index hospitalization, mean (SD)	2499996 (1652790)	2139109 (1039524)	**0.014**
Total cost by 30 days after discharge, mean (SD)	2662919 (1832164)	2227493 (1069763)	**<0.001**
Total cost by 90 days after discharge, mean (SD)	2989234 (2053859)	25438010 (1538120)	**<0.001**
Total cost by 365 days after discharge, mean (SD)	4071862 (3364657)	3214577 (2472251)	**<0.001**
SSI	71 (5.45)	21 (1.61)	**<0.001**
Post-operative pain, n (%)	242 (18.6)	219 (16.8)	0.26
Transfusion, n (%)	309 (23.7)	46 (3.53)	**<0.001**
Readmission, n (%)	134 (10.3)	71 (5.45)	**<0.001**
Post-operative ileus, n (%)	69 (5.29)	35 (2.68)	**<0.001**
Post-operative genitourinary complications, n(%)	34 (2.61)	21 (1.61)	0.10

Table 2

A total of 4,057 patients met inclusion and exclusion criteria. Using PSM, 1,304 pairs of patients were matched. **Table 1** shows the baseline characteristics of the enrolled patients.

dV arm had less healthcare resource usage with regard to both the length of hospitalization and medical cost. The post-operative outcomes in were also better for dV arm (**Table 2**).

Results: LAP surgery vs dV surgery

	Before PSM			After PSM		
	LAP (n=12021)	dV (n=1572)	P value	LAP (n=1572)	dV (n=1572)	P value
Age, mean (SD)	67.4 (11.3)	65.7 (11.6)	**<0.001**	65.7 (12.1)	65.7 (11.6)	0.93
Female, n (%)	4104 (34.1)	553 (35.2)	0.43	559 (35.6)	553 (35.2)	0.85
BMI, mean (SD)	23.0 (4.05)	22.90 (3.69)	0.14	22.8 (3.69)	22.9 (3.69)	0.66
Smoking history, n (%)	6602 (54.9)	887 (56.4)	0.27	904 (57.5)	887 (56.4)	0.56
Stage, n (%)						
1	3900 (32.4)	638 (40.6)	**<0.001**	627 (39.9)	638 (40.6)	0.71
2	2920 (24.3)	360 (22.9)	0.24	371 (23.6)	360 (22.9)	0.67
3	4122 (34.3)	472 (30.0)	**<0.001**	475 (30.2)	472 (30.0)	0.94
4	906 (7.54)	91 (5.79)	**0.014**	83 (5.28)	91 (5.79)	0.59
CCI, mean (SD)	7.33 (3.66)	6.93 (3.70)	**<0.001**	6.92 (3.62)	6.93 (3.70)	0.89

Table 3

	LAP (n=1572)	dV (n=1572)	P value
Total length of hospitalization, mean (SD)	20.1 (15.0)	18.0 (9.44)	**0.01**
Length after surgery, mean (SD)	17.2 (14.6)	15.387 (9.19)	**0.01**
Total cost of index hospitalization, mean (SD)	2176856 (1969402)	2101644 (958699)	0.16
Total cost by 30 days after discharge, mean (SD)	2272680 (1992171)	2182429 (988828)	0.72
Total cost by 90 days after discharge, mean (SD)	2559659 (2085268)	2477509 (1425334)	0.19
Total cost by 365 days after discharge, mean (SD)	3319353 (2588467)	3100546 (2305889)	**<0.001**
SSI	57 (3.63)	22 (1.40)	**<0.001**
Post-operative pain, n (%)	336 (21.4)	257 (16.3)	**<0.001**
Transfusion, n (%)	87 (5.53)	50 (3.18)	**0.002**
Readmission, n (%)	116 (7.38)	75 (4.77)	**0.003**
Post-operative ileus, n (%)	52 (3.31)	47 (2.99)	0.68
Post-operative genitourinary complications, n(%)	19 (1.21)	21 (1.34)	0.87

Table 4

A total of 13,593 patients met inclusion and exclusion criteria. Using PSM, 1,572 pairs of patients were matched. **Table 3** shows the baseline characteristics of the enrolled patients.

dV arm had less healthcare resource usage with regard to both the length of hospitalization and medical cost compared to LAP arm. Most post-operative outcomes were also better for dV arm (**Table 4**).

Conclusion:

Introduction of robotic surgery system may reduce overall healthcare costs and improve post-operative outcomes in rectal cancer field.

[COI Disclosure]

Lecture fees: Novo Nordisk Pharma Ltd., Novartis Pharma Inc.

Funded research: Intuitive surgical Inc., Eisai Inc.

Endowed Chair Affiliation: Takeda Pharmaceuticals Inc.